The 21st Century Venture Capital Research Institute released the “2023-2024 Medical and Health Investment Competitiveness Research Report” and cases. The report and cases seek to comprehensively show the trend changes in the field of medical and health investment in the past year (July 2023 – June 2024), hoping to help investment institutions judge and adjust the direction of investment.
Qiming Venture Capital has been awarded the annual Influence Pharmaceutical health investment competitiveness Venture capital and private equity investment institution for many consecutive years; Chen Kan, partner of Qiming Venture Capital, won the Annual Influential medical and Health Investor.
21st Century Venture Capital Research Institute interpreted the data of medical and health investment and financing, observed the trend, and took stock of the investment situation in key segments. At the same time, through the visits of first-line investment institutions, industry questionnaires, and referring to CVSource investment data, ZERONE and other data, we learned about the fundraising and exit of many medical and health investment institutions.
As well as the performance of the subsequent round of financing of the invested project, combined with the objective and fair comprehensive evaluation of the ESG investment indicators of the participating research institutions by the industry expert committee, the “2023-2024 Medical and Health Investment Competitiveness Study Case” is launched.
According to the statistics of CVSource investment data, the 21st Century Venture Capital Research Institute found that between July 2023 and June 2024, from the investment stage, the trend of venture capital institutions investing in both ends is more and more obvious. On the one hand, venture capital institutions pay more attention to early investment and small investment.
On the other hand, mergers and acquisitions are becoming more active. From the perspective of subdivision, the biomedical field accounts for the largest proportion of financing events, followed by medical devices, followed by medical services, medical technology, other fields of medicine and health, and medical informatization.
With the rapid breakthrough of cutting-edge biotechnology and artificial intelligence technology, the development of the pharmaceutical and health industry has shown strong momentum. 21st Century Venture Capital Research Institute noted that, on the one hand, continuous breakthroughs in cell technology, nucleic acid technology, targeted protein degradation technology, etc.,have brought more optimized and low-cost programs for disease treatment.
On the other hand, the application of artificial intelligence and digital technology has brought revolutionary impact to the development of the pharmaceutical and health industry.
In recent years, the license-out (external authorization) model of innovative drugs in China is gradually hot. The relevant transactions not only highlight the global capital’s high recognition of Chinese Biotech’s technological innovation and target differentiation capabilities, but also show the coping strategies and global layout capabilities of outstanding domestic Biotech companies.
In view of the investment direction in the field of medicine and health segmentation in 2023-2024, the 21st Century Venture Capital Research Institute found that the trend of localization and high-end of medical devices was obvious; The rise of local innovation in surgical robots; ADC is becoming one of the most concerned segments in the field of innovative drugs, and it is booming.
The development of synthetic biology from “technology” to “industry” of biological manufacturing; Under the influence of AI, two structural opportunities of digital infrastructure and digital innovative products have emerged in the field of digital healthcare. The silver economy is heating up, and the medical field, as an important part of the related industry chain, has received high market attention.
Related topics
